Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 1/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.37 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14445500 | 0.82 | PRMT3 (0.33) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL260446 | 0.82 | ALDH1A1 (0.33) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL24036624 | 0.82 | PRMT3 (0.33) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL14271348 | 0.80 | PRMT3 (0.32) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL15907847 | 0.80 | PRMT3 (0.32) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL1644155 | 0.80 | PRMT3 (0.32) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL1832441 | 0.80 | PRMT3 (0.39) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL12933032 | 0.79 | ALDH1A1 (0.35) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL1834034 | 0.78 | CA12 (0.41) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL1831672 | 0.78 | PRMT3 (0.37) | PRMT3CARM1PRMT6PRMT1PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022261030-A1 | OLIGONUCLEOTIDE ANALOGUE MODULATORS OF ONCOGENES | NEUBASE THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261029-A2 | PEPTIDE NUCLEIC ACID THERAPEUTICS FOR TRINUCLEOTIDE REPEAT DISORDERS | NEUBASE THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022132194-A2 | OLIGONUCLEOTIDE ANALOGUE THERAPEUTICS FOR TREATMENT OF NEUROMUSCULAR DISEASE | NEUBASE THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20120115136-A1 | PNA DIAGNOSTIC USE | PNA Patent Owners (a/k/a CIG) (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115136-A1 | PNA DIAGNOSTIC USE | PNA Patent Owners (a/k/a CIG) (US) | 2012-05-10 | — | — | US | disclosed |
| US-7378485-B2 | Peptide nucleic acids with polyamide-containing backbones | BUCHARDT OLE | 2008-05-27 | — | — | US | disclosed |
| US-7378485-B2 | Peptide nucleic acids with polyamide-containing backbones | BUCHARDT OLE | 2008-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115136-A1 | PNA DIAGNOSTIC USE | RNASE1, NCL, PABPC4 | PRMT3 2262/4885CARM1 2819/4885PRMT6 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.